Opioid-Related Disorders Clinical Trial
Official title:
Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection
Using combination of opioid analgesics and analgesics with different mechanism of action the investigators can decrease the consumption of opioid analgesics and their side effects. The investigators will use opioid analgesic fentanyl alone or in combination with dexmedetomidine or lidocaine.The participants scheduled for laparoscopic intestine resection will be divided in three groups: in the first group, the participants will receive single boluses of fentanyl, in the second group, the participants will receive continuous infusion of lidocaine and single boluses of fentanyl, and in the third group, the participants will receive continuous infusion of dexmedetomidine and single boluses of fentanyl. Participants with intraoperative infusion od dexmedetomidine or lidocaine will need less boluses of fentanyl during the operation and less opioid analgesics after the operation in comparison to those who will receive only fentanyl boluses. Better cognitive function after the operation is expected in participants receiving dexmedetomidine infusion. There will be minimal incidence of neuropathic pain because of minimal surgical injury of peripheral nerves in all groups of patients.
Introduction: The consumption of opioid analgetics and their side effects can be minimized
by using the combination of opioid analgesics and analgesics with different mechanism of
action. The investigators will use opioid analgesic fentanyl alone or in combination with
dexmedetomidine or lidocaine. Dexmedetomidine is alpha 2 adrenergic receptor agonist and is
used more and more during anesthesia because of its anesthetic and analgesic effects as it
preserves mental status and decreases the consumption of analgesics. Lidocaine is a local
anesthetic and antiarrhythmic drug which decreases opioid consumption as well.
The participants scheduled for laparoscopic intestine resection will be divided in three
groups: in the first group, the participants will receive single boluses of fentanyl, in the
second group, the participants will receive continuous infusion of lidocaine and single
boluses of fentanyl, and in the third group, the participants will receive continuous
infusion of dexmedetomidine and single boluses of fentanyl.
Hypothesis: Participants with intraoperative infusion od dexmedetomidine or lidocaine will
need less boluses of fentanyl during the operation and less opioid analgesics after the
operation in comparison to those who will receive only fentanyl boluses. Better cognitive
function after the operation in participants receiving dexmedetomidine infusion is expected.
There will be minimal incidence of neuropathic pain because of minimal surgical injury of
peripheral nerves in all groups.
Justification: Lidocaine and dexmedetomidine are analgesics with different mechanism of
action in comparison to opioid analgesics. Their use during the operation decreases the
consumption of opioids intra- and postoperatively. Dexmedetomidine has beneficial effect on
cognitive function and that is why the investigators expect preserved cognitive function in
participants after the operation. Because of minimal surgical injury and, therefore, minimal
probability of peripheral nerve injury, the investigators expect low incidence of
neuropathic pain in all groups.
Methods: The investigators will include 60 participants in the study, between 35 to 85 years
old, ASA 2 - 3 (American Society of Anesthesiologists, ASA) undergoing a planned
laparoscopic intestine resection. The participants will be randomized into three groups. In
the first group, fentanyl boluses will be adimistred during the operation, in the second,
infusion of lidocaine will be added to fentanyl, and in the third, the infusion of
dexmedetomidine will be added to fentanyl. The investigators will record opioid consumption
during the operation and two days after the operation. The investigators will use mini
mental test for evaluation of cognitive function before the operation and at the transfer of
the participant postoperatively to the surgical ward, in order to explore the influence of
analgesics used on cognitive function. Two months after the operation the degree of
neuropathic pain will be evaluated with pain questionnaire. The data will be statistically
evaluated.
Expected results: Participants with intraoperative infusion of lidocaine and dexmedetomidine
will need less opioid analgesics during and after the operation in comparison to the group
with fentanyl boluses only. The investigators expect better cognitive function after the
operation in participants with dexmedetomidine infusion. Because of the minimal surgery
injury to the peripheral nerves low incidence of neuropathic pain is expected in all groups.
Study design and methods Inclusion criteria: In our study the investigators will include
patients aged 35 to 85, ASA 2-3 (according to the classification of American Society of
Anesthesiologists), undergoing a planned laparoscopic intestine resection at the Department
of Abdominal Surgery at the University Medical Centre Ljubljana. Included participants will
sign the consensus for participating in the study after exact explanation and conversation,
as well as consensus for anesthesia and surgery.
Exclusion criteria: Participants with allergies to alpha 2 receptor agonists, uncontrolled
arterial hypertension, 2nd and 3rd degree atrioventricular block, alcohol and illegal drugs
abusers, patients with clinically important neurological, cardiovascular, respiratory (COPD,
emphysema), renal, liver, and gastrointestinal disease, will be excluded from our study. The
investigators will also exclude pregnant women and patients younger than 18 years due to
their physiological particularities.
Data collection: The participants will be prepared for the operation as usual according to
the operative protocol. Cognitive function is going to be assessed with a mini mental test
before the operation.
After inserting the peripheral venous line, the induction will be performed with analgesic
fentanyl (2 mcg/kg) and sedative propofol (1,5-2,5 mg/kg). Muscle relaxant rocuronium will
be used for easier intubation (0,6 mg/kg; standard dose). The participants will be
controlled mechanically ventilated with tidal volumes 6-8 ml/kg. Anesthesia will be
maintained with intravenous anesthetic propofol in doses between 4 - 6 mg/kg/h according to
bispectral index value (bispectral index, BIS, Vista), which will be kept between 40 and 55,
the interval suitable for surgical depth of anesthesia. Normothermia and normocapnia will be
maintained. The fluids will be warmed to 39°C via Hotline, the body temperature and expired
CO2 will be measured. Mean arterial blood pressure will be maintained within ± 25 % baseline
value. When mean arterial blood pressure will decrease more than 25% from the baseline
value, a bolus of a vasoactive drug will be used.
Beside the standard monitoring (electrocardiogram, pulse oximetry, indirect blood pressure
management, capnometry), the investigators will use ANI (analgesia nociception index)
monitoring for the pain measurement. ANI values will be maintained between 50 and 70 and
between those valuse good analgesia is provided. Muscle relaxation will be measured with TOF
(train of four) and will be maintained on the level of deep muscle relaxation, that is TOF 0
and PTC 1 - 2 (posttetanic count).
Before the operation the investigators will randomize the participants into the three
groups, which will distinguish according to analgesia used. All participants will get
intravenous bolus of fentanyl (2 mcg/kg, standard dose) before the incision. All of them
will receive bolus of fentanyl when ANI will drop below 50 during the operation (2 mcg/kg,
recommended standard dose, first group). Participants in the second group will receive
infusion of lidocaine (1,5 mg/kg/h), and participants in the third group infusion of
dexmedetomidine (0,5 µg/kg/h). The consumption of fentanyl and propofol will be measured
during the operation. The infusion of lidocaine and dexmedetomidine will be stopped 10
minutes before the end of the operation. Propofol infusion will be stopped at the end of the
final suture. After the operation all participants will receive postoperative infusion of
piritramide delivered with PCA (patient control analgesia). If the pain according to the
visual analog scale (VAS) will be more than 3, the participants will be given a bolus of the
peripheral acting analgesic or opioid (paracetamol, metamizol, piritramide). VAS will be
reevaluated two days after the operation, as well as the consumption of other opioids and
other analgesics. Cognitive function will be evaluated again on the second day with mini
mental test, or at the transfer of the participant to the surgical ward with the
discontinuation of the opioids and when they will be afebrile. Neuropathic pain will be
evaluated with the pain questionnaire two months after the operation.
Statistical analysis: Collected data will be presented using descriptive statistics such as
mean, median and standard deviation. The use of the opioids and other analgesics will be
compared using paired Student t-test or other suitable nonparametric tests (eg. ANOVA),
depending on the type of data used.
Correlation of different factors will be determined using Pearson/Spearman correlation
coefficient. Deviation from normal distribution of data will be tested with a chi-squared
test. Predictive value will be determined using logistic regression.
Expected results: The investigators assume that there will be less opioid consumption in
participants receiving lidocaine or dexmedetomidine infusion during the operation and the
following two days compared to participants who received fentanyl boluses only. In
participants with intraoperative infusion of dexmedetomidine the investigators expect
preserved cognitive function. Low incidence of neuropathic pain is expected two months after
the operation in all groups because of minimal peripheral nerve injury during operation.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03950492 -
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder
|
N/A | |
| Completed |
NCT00000335 -
Activity Monitoring Assessment of Opiate Withdrawal - 4
|
Phase 2 | |
| Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
| Enrolling by invitation |
NCT06084221 -
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems
|
N/A | |
| Completed |
NCT02978417 -
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
|
Phase 4 | |
| Withdrawn |
NCT03137017 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
|
Phase 1 | |
| Withdrawn |
NCT03137030 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
| Completed |
NCT00710385 -
Abuse Liability of Suboxone Versus Subutex
|
Phase 3 | |
| Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
| Completed |
NCT00218309 -
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
|
Phase 2 | |
| Terminated |
NCT00000243 -
Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone
|
N/A | |
| Completed |
NCT00067184 -
Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
|
||
| Completed |
NCT00000264 -
Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16
|
N/A | |
| Completed |
NCT00000257 -
Effects of Alcohol History on Effects of Nitrous Oxide - 9
|
N/A | |
| Completed |
NCT00000279 -
Novel Medications for Opiate Detoxification - 4
|
Phase 2 | |
| Completed |
NCT00000306 -
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
|
Phase 2 | |
| Completed |
NCT00000249 -
Effects of Subanesthetic Concentrations of Nitrous Oxide - 1
|
Phase 2 | |
| Recruiting |
NCT04933084 -
Pre-operative Education Modalities to Decrease Opioid Use
|
N/A | |
| Recruiting |
NCT03610672 -
Mobile Intervention for Young Opioid Users
|
N/A |